Comparison of intravenous syntocinon in the third stage of labor with rectal misoprostol abortions after the second trimester of pregnancy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015020715795N2

Enrollment

100

Registered

2015-03-15

Start date

2014-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intravenous syntocinon in the third stage of labor associated with rectal misoprostol abortions after the second trimester of pregnancy. Oxytocic drugs

Interventions

Intervention 1: Two hundred micrograms of misoprostol administered vaginally every 6 hours with 40 units of syntocinon intravenously. Intervention 2: Two hundred micrograms of misoprostol administered

Treatment - Drugs

Two hundred micrograms of misoprostol administered vaginally every 6 hours with 40 units of syntocinon intravenously

Two hundred micrograms of misoprostol administered vaginally every 6 hours with 400 mcg of misoprostol rectal

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria were: legal permission to go to the end of pregnancy; intrauterine fetal death; gestational age 14 to 18 weeks; premature rupture approved exclusion criteria of the study: allergy or intolerance known as misoprostol; high blood pressure 160/90; severe cardiovascular disease; the patient's general condition is very bad; history of previous uterine scar (except single layer lower uterine segment caesarean section with a transverse incision); severe anemia; coagulation; anticoagulation; active liver disease; uncontrolled seizure disorders; Addison's disease; steroid use

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The time of placental removal. Timepoint: After fetus delivery. Method of measurement: Time.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Nooshin Mobaraki

Ardabil University of Medical Sciences

n.mobaraki@arums.ac.ir+98 45 3323 5033

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026